Neubase therapeutics, inc. (OHRP)
Income statement / Yearly
Sep'19Sep'18Sep'17Sep'16Sep'15Sep'14Sep'13Sep'12Sep'11Sep'10
REVENUES

-

-

-

-

-

-

-

-

0

0

COST OF SALES

-

-

-

-

-

-

-

-

0

0

GROSS PROFIT

-

-

-

-

-

-

-

-

0

0

OPERATING EXPENSES
General and administrative

9,095

3,634

5,278

7,656

7,509

4,287

1,775

135

104

96

Professional fees

-

-

-

-

-

-

-

875

338

362

Research and development

4,273

4,319

17,406

16,460

8,777

4,369

2,753

1,625

521

302

Research and development expense- license acquired

12,967

-

-

-

-

-

-

-

-

-

Change in derivative liability

-

-

-

-

-

-

-1,117

1,812

-3,977

1,480

Change in fair value of contingent consideration

-

-

-

1,185

-2,637

-

-

-

-

-

Loss on Impairment of intangible asset

-

5,313

-

-

-

-

-

-

-

-

Gain on settlement of liabilities

-

1,228

70

710

-

-

-

-

-

-

Impairment of Intangibles

-

-

-

-

338

-

-

-

-

-

Salaries and wages

-

-

-

-

-

-

-

649

279

254

TOTAL OPERATING EXPENSES

26,336

-

-

-

-

-

-

3,286

1,243

1,015

LOSS FROM OPERATIONS

-26,336

-13,903

-23,780

-24,596

-17,805

-9,122

-4,620

-3,286

-1,243

-1,015

OTHER INCOME (EXPENSE)
Depreciation and amortization

-

1,124

1,165

1,189

1,179

466

91

-

-

-

Loss on impairment of goodwill

-

740

-

-

-

-

-

-

-

-

Interest expense

128

-

-

-

-

-

4

1

2

21

Change in fair value of warrant liabilities

492

-

-

-

-

-

-

-

-

-

Equity in losses on equity method investment

-

-

-

-

-103

-10

-

0

-

-

Total other expenses

621

-

-

-

-

-

-

-

-

-

Royalty income

-

-

-

-

35

-

-

-

-

-

Gain on sale of assets

-

-

-

-

-

-

-

-

70

0

Gain on settlement of debt

-

-

-

-

-

-

-

21

49

19

Total other expense, net

-

592

-1

3

42

8

90

0

1

31

Interest income (expense), net

-

74

-29

12

-5

-5

-

-

-

-

Total Other Income

-

667

-30

-1,170

2,607

-7

-1,031

1,831

-3,858

1,509

LOSS FROM OPERATIONS BEFORE INCOME TAXES

-

-

-

-25,766

-15,197

-9,130

-5,652

-1,454

-5,101

494

INCOME TAXES

-

-13,236

-23,810

-

-

-

-

-

0

0

LOSS BEFORE DISCONTINUED OPERATIONS

-

-

-

-

-

-

-

-

-5,101

494

Income from discontinued operations(including gain on disposal of $606,000)

-

-

-

-

-

-

-

-

0

0

Income tax benefit

-

-

-

-

-

-

-

-

0

0

GAIN ON DISCONTINUED OPERATIONS

-

-

-

-

-

-

-

-

0

0

NET LOSS

-26,958

-13,236

-23,810

-25,766

-15,197

-9,130

-5,652

-1,454

-5,101

494

Continuing operations

-

-

-

-

-

-

-

-

-0.13

0.02

Discontinued operations

-

-

-

-

-

-

-

-

0.00

0.00

BASIC AND DILUTED LOSS PER SHARE (in dollars per share)

-3.26

-0.23

-0.53

-0.82

-0.54

-0.41

-0.30

-0.10

-0.13

0.02

WEIGHTED AVERAGE SHARES OUTSTANDING:
BASIC AND DILUTED

8,271

56,399

44,770

31,349

28,404

22,141

18,707

14,242

38,666

32,821